Attia Mai S, Elewa Gasser M, Abdelgawad Nora, Ismail Radwa M, Hassan Eid Mohamed, Ghoneim Mohamed M
Department of Oral Medicine, Periodontology, Diagnosis, and Radiology, Faculty of Dental Medicine for Girls, Al-Azhar University, Cairo, EGY.
Department of Periodontology, Oral Diagnosis, and Oral Radiology, Faculty of Oral and Dental Medicine, Misr International University, Cairo, EGY.
Cureus. 2023 Mar 23;15(3):e36559. doi: 10.7759/cureus.36559. eCollection 2023 Mar.
Background Low-level laser treatment (LLLT) was thought to increase bone quality during osseointegration when combined with dental implants. However, there is no sufficient information on its impact on dental implants in diabetics. Osteoprotegerin (OPG) has been described as a marker for bone turnover to determine implant prognosis. The current research aims to evaluate the effect of low-level laser therapy (LLLT) on bone density (BD) and osteoprotegerin levels in peri-implant crevicular fluid (PICF) in type II diabetic patients. Methods This study comprised 40 individuals with type II diabetes mellitus (T2DM). Implants were randomly placed in 20 non-lasered T2DM patients (control) and 20 lasered T2DM patients (LLLT group). At the follow-up stages, BD and OPG levels in the PICF were evaluated in both groups. Results Significant variations were shown among control and LLLT groups concerning OPG level and BD (p≤0.001). OPG was significantly decreasing with follow-up points (p≤0.001). There was a significant decrease in OPG with time in both groups with a higher decrease in the control group. Conclusion LLLT is promising in controlled T2DM patients due to its outstanding influence on BD and estimated crevicular levels of OPG. Regarding its clinical significance, LLLT significantly improved bone quality during osseointegration on dental implants in T2DM. LLLT is considered potentially important for T2DM patients during implant placement. Trial registration The study was registered on ClinicalTrial.gov under registration number NCT05279911 (registration date: March 15, 2022) (https://clinicaltrials.gov/ct2/show/NCT05279911).
背景 低强度激光治疗(LLLT)被认为在与牙种植体结合时可提高骨整合过程中的骨质量。然而,关于其对糖尿病患者牙种植体的影响,目前尚无足够信息。骨保护素(OPG)已被描述为骨转换的标志物,用于确定种植体预后。本研究旨在评估低强度激光治疗(LLLT)对II型糖尿病患者种植体周围龈沟液(PICF)中骨密度(BD)和骨保护素水平的影响。方法 本研究纳入40例II型糖尿病(T2DM)患者。将种植体随机植入20例未接受激光治疗的T2DM患者(对照组)和20例接受激光治疗的T2DM患者(LLLT组)。在随访阶段,评估两组PICF中的BD和OPG水平。结果 对照组和LLLT组在OPG水平和BD方面存在显著差异(p≤0.001)。OPG水平随随访时间显著降低(p≤0.001)。两组OPG水平均随时间显著降低,对照组下降幅度更大。结论 LLLT对BD和估计的龈沟OPG水平有显著影响,在控制良好的T2DM患者中具有应用前景。就其临床意义而言,LLLT显著改善了T2DM患者牙种植体骨整合过程中的骨质量。LLLT被认为在T2DM患者种植体植入过程中具有潜在重要性。试验注册 本研究已在ClinicalTrial.gov上注册,注册号为NCT05279911(注册日期:2022年3月15日)(https://clinicaltrials.gov/ct2/show/NCT05279911)。